Teva Reports Encouraging Data From Late-Stage Schizophrenia Trial
- Teva Pharmaceuticals Industries Ltd (NYSE: TEVA) announced results from the Phase 3 trial comparing TV-46000/mdc-IRM once monthly (q1m) and TV-46000/mdc-IRM once every two months (q2m) with placebo for schizophrenia patients who underwent stabilization on oral risperidone.
- Results showed treatment with TV-46000 (overall, q1m or q2m) significantly prolonged time to relapse, decreased proportions of patients with impending relapse at week 24, and demonstrated a significant increase in proportions maintaining stability.
- The most common adverse reactions were nasopharyngitis, increased weight, and extrapyramidal disorder.
- Time to impending relapse significantly favored TV-46000 with overall: 0.283; q1m: 0.200 and q2m: 0.375 versus placebo.
- TV-46000 also prolonged the time to relapse by 3.5, 5.0, and 2.7 times, respectively, versus placebo.
- Proportions of patients with impending relapse at week 24 were significantly lower for TV‑46000 (overall: 9%; q1m: 7%; q2m: 11%) versus placebo (28%).
- Price Action: TEVA shares are up 2.06% at $8.92 during the premarket session on the last check Monday.
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Posted-In: Briefs Phase 3 TrialBiotech News Health Care Movers Trading Ideas General
